HYPHENS PHARMA INTL LIMITED (1J5) Fair Value & Analysis
Healthcare · SG · Market cap 108M SGD
Fair value as of: Aug 13, 2026
From 24 valuation models · updated 4 days ago
Share price +4.3% over the past month.
A solid business, currently priced close to our fair value.
What matters now
- The price sits close to our fair value, market and models broadly agree here, little valuation tension.
- Our model range runs from 0.3000 SGD (bear) to 0.5000 SGD (bull), base 0.4000 SGD. The closer the price sits to the lower half, the larger the margin of safety.
- Quality 74/100 (solid quality) with high evidence: the data supports the verdict.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range 0.2057 SGD – 0.3750 SGD · fair‑value band 0.3000 SGD – 0.5000 SGD · the 0.3650 SGD price screens below the 0.4000 SGD fair value. Dashed = 300-day average. As of Aug 13, 2026.
Analysis
HYPHENS PHARMA INTL LIMITED (1J5) currently trades at 0.3650 SGD, while our model-based Fair Value estimate is 0.4000 SGD, implying the stock looks roughly 9.6% fairly valued today. The Quality Score stands at 74/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, HYPHENS PHARMA INTL LIMITED generated revenue of 177M SGD at a net margin of 3.3%. Revenue declined 15.4% year over year. It earns a return on equity of 8.3%. The stock trades on a trailing P/E of 18.3. Fundamentals as of Aug 13, 2026
Our scenario range runs from 0.3000 SGD (bear case) to 0.5000 SGD (bull case); at 0.3650 SGD, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 4% below its 52-week high and 31% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -7% fair-value upside, at 10%, 1J5 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 24 models by family
Widest divergence: DCF Models (0.7100 SGD) versus Earnings-Based (0.1200 SGD). Highest evidence: Growth DCF (80).
Notify me when 1J5 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 75 · Market factors (momentum, volatility) 74
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Hyphens Pharma International Limited, together with its subsidiaries, operates as a specialty pharmaceutical and consumer healthcare company primarily in Singapore, Vietnam, Malaysia, and internationally. It operates through Pharmaceutical and Medical Aesthetics; Proprietary Brands; and Digital Platform and E-Pharmacy segments.
Full company description
Hyphens Pharma International Limited, together with its subsidiaries, operates as a specialty pharmaceutical and consumer healthcare company primarily in Singapore, Vietnam, Malaysia, and internationally. It operates through Pharmaceutical and Medical Aesthetics; Proprietary Brands; and Digital Platform and E-Pharmacy segments. The Pharmaceutical and Medical Aesthetics segment markets and sells a range of pharmaceutical and medical aesthetics products, including the Stérimar nasal sprays, Bausch+Lomb eye drops, Vivomixx, Fenosup Lidose, and Piascledine products in ASEAN countries. This segment focuses on various therapeutic areas, such as dermatology, pediatrics and neonatology, allergy, otorhinolaryngology, orthopedics and rheumatology, radiology, cardiology and interventional cardiology, ophthalmology, gastroenterology, psychiatry, family medicine, and medical aesthetics. Its Proprietary Brands segment develops, markets, and sells dermatological products comprising Ceradan, TDF, and CG210; health supplements under the Ocean Health brand covering areas, such as heart, joint, physical, cognitive, eye, and health; and pharmaceuticals. The Digital Platform and E-Pharmacy segment operates a digital platform that services procurement needs of healthcare professionals, healthcare institutions, and retail pharmacies primarily in Singapore. The company was formerly known as Hyphens Pharma International Pte Ltd and changed its name to Hyphens Pharma International Limited in May 2018. Hyphens Pharma International Limited was founded in 1998 and is headquartered in Singapore.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
HYPHENS PHARMA INTL LIMITED reported revenue of 177M SGD in FY2025 versus 126M SGD in FY2021, a compound +8.9%/yr. Reported net income was 5.8M SGD in FY2025, compounding −3.9%/yr from FY2021.
Watch 1J5: get an alert when its fair value changes →
Peer Group
Medical Distribution · 77 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Distribution median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Distribution stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| McKesson Corporation MCK | $878.73 | $819.31 | -7% |
| Cencora, Inc COR | $314.17 | $211.07 | -33% |
| Cardinal Health, Inc CAH | $234.16 | $141.77 | -39% |
| Henry Schein, Inc HSIC | $90.74 | $71.70 | -21% |
| Shanghai Pharmaceuticals Holding 601607 | ¥16.56 | ¥33.96 | +105% |
| Sinopharm Group 1099 | HK$16.75 | HK$58.67 | +250% |
| Galenica AG GALE | CHF 80.85 | CHF 61.79 | -24% |
| Guangzhou Baiyunshan Pharmaceutical Holdings 600332 | ¥21.49 | ¥28.65 | +33% |
| Jointown Pharmaceutical Group 600998 | ¥5.04 | ¥9.84 | +95% |
| Asker Healthcare Group ASKER | kr 80.00 | kr 28.26 | -65% |
Compare HYPHENS PHARMA INTL LIMITED with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is HYPHENS PHARMA INTL LIMITED (1J5) overvalued or undervalued?
What is the fair value of 1J5?
What is the quality score of 1J5?
What is the revenue of HYPHENS PHARMA INTL LIMITED (1J5)?
What is the net profit margin of 1J5?
Does HYPHENS PHARMA INTL LIMITED pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track HYPHENS PHARMA INTL LIMITED and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.